Consistent and clinically relevant effects with fentanyl buccal tablet
in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain.
The most common adverse events associated with fentanyl buccal tablet
use were nausea, vomiting, fatigue, constipation, anemia, and peripheral edema.
Fentanyl buccal tablet
(FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebo-controlled study.
The ongoing phase II trial with clonidine Lauriad([R]) was also presented: y A phase II, multicentre, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad([R]) 50 g and 100 g mucoadhesive buccal tablet
(MBT) applied once daily in the prevention and treatment of chemoradiotherapy-induced oral mucositis in patients with head and neck cancer e.
Results on two European phase III studies were also presented in two posters entitled: "Miconazole Mucoadhesive Buccal Tablet
for the Treatment of Oropharyngeal Candidiasis in Head and Neck Cancer Patients" and "Evaluation of Miconazole MucoAdhesive Buccal Tablet
: a novel once daily antifungal treatment for Oropharyngeal Candidiasis".
This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad[R] 50mg Mucoadhesive Buccal Tablet
(MBT) versus matching placebo in patients suffering from recurrent oro-facial herpes.
Miconazole Lauriad[R] delivers the antifungal miconazole via a mucoadhesive buccal tablet
that is designed to enable once-daily dosing of the active ingredient at the site of infection.
BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on therapy and supportive care in cancer and AIDS, today announced Europe-wide approval for embossing its Loramyc([R]) mucoadhesive buccal tablet
, developed for the treatment of oropharyngeal candidiasis.
At the American Conference for the Treatment of HIV (ACTHIV) that took place on May 15-17, 2009 in Denver, Colorado, USA, BioAlliance Pharma presented the poster: "Once-Daily Miconazole Mucoadhesive Buccal Tablet
is an Effective and Safe Treatment for Oropharyngeal Candidiasis".
Crushing sublingual and buccal tablets
can alter their effectiveness.
DARA holds exclusive US marketing rights to Gelclair oral rinse gel, Oravig (miconazole) buccal tablets
and Soltamox (tamoxifen citrate oral liquid solution).
Formulation and evaluation of mucoadhesive buccal tablets
of sumatriptan succinate.